Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL205 in advanced solid tumors
NCT06459973Phase 2Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Jun 2024
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of YL205 in ovarian cancer, Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), renal cell carcinoma (RCC), endometrial cancer (EC), sponsored by MediLink Therapeutics. Started Jun 2024; status: recruiting.
02
Drugs
YL205
03
Conditions
ovarian cancerNonsquamous Non-Small Cell Lung Cancer (nsNSCLC)renal cell carcinoma (RCC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06459973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06459973.